Delivery Order SPE2DB22D1202-SPE2DB25FVEW5
Award Date 7/17/25
Potential Completion Date 7/18/25
Potential Value $1.9K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA), a defense agency. The $1,684.96 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on June 17, 2025, with a completion date of June 18, 2025. The contract is not set aside and does not mention any subcontractors. AmerisourceBergen Drug Corp holds a substantial $999,999,999.00...
- This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The $8,424.80 firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA), a defense agency. The contract has a completion date of July 8, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine products to the Defense Logistics Agency (DLA), a defense agency. The $2,106.20 fixed-price delivery order has a performance period through May 19, 2025 and was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp also holds a $999,999,999.00 Indefinite Delivery...
- This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for a firm fixed price of $1,684.96 with a performance period ending on July 17, 2025. The contract is a delivery order and is not a set-aside. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the U.S. government. The contract, valued at $1,684.96, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of July 10, 2025. It is not designated as a set-aside contract, indicating open competition....
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $6,309.12 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a period of performance through November 4, 2024. This contract is a child task order under AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract, valued at $69,524.40, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of September 11, 2024. The contract is not designated with a set-aside requirement, indicating open competition....
- This federal contract award is for the delivery of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML to the Defense Logistics Agency (DLA). The fixed-price delivery order, valued at $8,856.30, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 14, 2025. The contract has an ultimate completion date of May 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,671.42 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The contract has an ultimate completion date of June 30, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,521.26 firm fixed-price delivery order is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of June 25, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...